Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"Pertuzumab"”.
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… alternative HER2-targeted therapies, such as pertuzumab, margetuximab, T-DM1, T-DXd, lapatinib, neratinib, pyrotinib, gefitinib, and tucatinib, have been developed. Nonetheless, despite of their improved effectiveness, de novo and acquired resistance to current treatments are very common in BC …
-
Rational design, characterization and in vivo studies of antibody mimics against HER2
… approach based on molecular interactions of HER2-Pertuzumab complex and Knob-Socket model can be developed to design antibody mimics for targeting HER2. All designed antibody mimics were simulated and docked with HER2 using Molecular Operating Environment (MOE) software to estimate binding energy …
-
Leveraging Antibodies for Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Cancer
… (PET) imaging agent, <sup>89</sup>Zr-DFO-pertuzumab, in mouse models of human breast cancer. In the second part, we developed two imaging agents for ovarian cancer, <sup>89</sup>Zr-DFO-AR20.5 for PET and <sup>ss</sup>B43.13-IR800 for near-infrared fluorescence imaging and evaluated their …
-
Metabolic vulnerability in HER2-positive Breast Cancer
… including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an antibody-drug conjugate (trastuzumab emtansine), have significantly prolonged the overall survival of HER2-positive breast cancer patients. However, almost all patients develop …
-
Costo-efectividad de la biopsia líquida para definir cambio farmacológico en cáncer de mama HER2 + avanzado en Colombia
… y segunda línea de tratamiento (Trastuzumab, Pertuzumab, Docetaxel y TDM1 respectivamente), resistencia , desenlaces, sensibilidad y especificidad de la prueba para detectar resistencia molecular. La efectividad se midió mediante AVAC y los costos fueron obtenidos de bases de datos de validez …
-
The Development of Novel Radioimmunoconjugates for the PET Imaging and Radioimmunotherapy of Cancer
… to prepare [<sup>89</sup>Zr]Zr-<sup>SSK</sup>DFO-pertuzumab for visualizing HER2+ breast cancer. Further, we introduce a new mAb with a catalytic domain that allows for the site-selective bioconjugation of chelators to yield [<sup>177</sup>Lu]Lu-CHX-A”-DTPA-PODS-HER2DVD for targeting HER2+ breast …
-
The perioperative setting as a platform for breast cancer biomarker development
… imaging [baseline and 15 days after trastuzumab/pertuzumab (HP) initiation (C1D15)] and tumour biopsy collection (3). The primary hypothesis was that early measurements of tumour maximum standardised uptake value corrected for lean body mass (SULmax) on PET/CT would predict pCR to HP. Results …